Published
Optimizando farmacoterapia mediante la deprescripción: reporte de caso
Optimizing pharmacotherapy through deprescription: Case report
DOI:
https://doi.org/10.15446/rcciquifa.v49n1.86736Keywords:
Polifarmacia, deprescripción, prescripción inapropiada, interacciones farmacológicas, reacciones adversas (es)Polypharmacy, deprescription, inappropriate prescription, drug interactions, drug-related side effects and adverse reactions (en)
Downloads
La polifarmacia es el uso simultáneo o excesivo de varios medicamentos y ha presentado una tendencia al aumento durante los últimos años, al igual que los cuadros clínicos asociados a interacciones farmacológicas secundarias, llevando así a adicionar cada vez más medicamentos, esto genera el fenómeno de cascada en la prescripción. En este artículo se presenta un caso de una mujer de 34 años, identificado desde una plataforma transaccional de registro de medicamentos prescritos de una EPS, a quien se realizó seguimiento de su tratamiento farmacológico ambulatorio durante 7 meses, en los cuales presentó persistencia de polifarmacia. Se identificó en el caso posibles errores en medicación y posibles ajustes a la terapia que disminuirían el riesgo de interacciones o cascada de prescripción.
Polypharmacy is the simultaneous use or excess of dosage of medicines and it has shown a tendency to increase in recent years, as well as the clinical symptoms associated with secondary drug interactions, thus leading to the addition of more and more medications, generating the cascade phenomenon of prescription. We present a case of a 34-year-old woman, identified from a transactional platform of registration of prescribed drugs of an EPS, who was followed up on her outpatient pharmacological treatment for 7 months, in which she presented persistent polypharmacy. It was identified in the case possible errors in medication and possible adjustments to the therapy that would decrease the risk of interactions or prescription cascade.
References
J.S. Sabogal-Carmona, E.A. Díaz-Rodríguez, Fundamentos de farmacovigilancia, Secretaría Distrital de Salud de Bogotá, Bogotá, 2013, pp. 26-36.
Xanax (alprazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Co; December 2016. URL: https://catalogo.fucsalud.edu.co:2074/contents/alprazolam-drug-information?search=alprazolam&source=panel_search_result&selectedTitle=1~117&usage_type=panel&kp_tab=drug_general&display_rank=1#references. Consultado en mayo de 2018.
Carbamazepine [prescribing information]. North Wales, PA: Teva; September 2014. URL: https://catalogo.fucsalud.edu.co:2074/contents/carbamazepine-drug. Consultado en mayo de 2018.information?search=carbamazepina&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#references
Lexicomp® Drug Interactions. URL: https://catalogo.fucsalud.edu.co:2074/drug-interactions/?source=responsive_home#di-document. Consultado en mayo de 2018.
S.M. Dursun, V.M. Mathew, MA, Reveley Toxic serotonin syndrome after fluoxetine plus carbamazepine, Lancet, 342(8868), 442-443 (1993).
Fluoxetine tablets [prescribing information]. Hauppauge, NY: ScieGen Pharmaceuticals Inc; May 2018. https://catalogo.fucsalud.edu.co:2074/contents/fluoxetine-drug-information?search=fluoxetine&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#references. Consultado en mayo de 2018.
Prozac (fluoxetine) [Prescribing information]. Indianapolis, en: Eli Lilly and Company, April 2011. URL: https://catalogo.fucsalud.edu.co:2074/drug-interactions/?source=responsive_home#di-document. Consultado en mayo de 2018.
J.W. Dietrich, K. Gieselbrecht, R.W. Holl et al., Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy, Horm. Metab. Res., 38(1), 57-59 (2016).
Administration FaD. 2016. Troxyca(R) ER oral extended-release capsules, oxycodone HCl naltrexone HCl oral extended-release capsules. URL: https://catalogo.fucsalud.edu.co:2074/contents/oxycodone-drug-information?search=OXYCODONE&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1. Consultado en mayo de 2018.
M. Justiniano, S. Dold, L.R. Espinoza, Rapid onset of muscle weakness (Rhabdomyolysis) associated with the combined use of simvastatin and colchicine, J. Clin. Rheumatol., 13, 266-268 (2007).
T.D. Bjornsson, J.T. Callaghan, H.J. Einolf, et al., The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective, J. Clin. Pharmacol., 43(5), 443-469 (2003).
A. Sánchez-Romero, A. Mayordomo-Aranda, R. García-Delgado, J.A. Durán-Quintana, Probable interaction between trazodone and carbamazepine, Pharmacopsychiatry, 44(4),158-159 (2011).
M. Shakoor, S. Ayub, A. Ahad, Z. Ayub, Transient serotonin syndrome cause by concurrent use of tramadol and selective serotonin reuptake inhibitor, Am. J. Case Rep., 15, 562-564 (2014).
S.O. Dalton, C. Johansen, L. Mellemkjaer, B. Nørgård, H.T. Sørensen, J.H. Olsen, Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study, Arch. Intern. Med., 163(1), 59-64 (2003).
S.R. Beach, W.J. Kostis, C.M. Celano, J.L. Januzzi, J.N. Ruskin, P.A. Noseworthy, J.C. Huffman, Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation, J. Clin. Psychiatry, 75(5), e441 (2014).
M. Haria, A. Fitton, D. McTavish, Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders, Drugs Aging, 4(4), 331 (1994).
W.B. Mendelson, A review of the evidence for the efficacy and safety of trazodone in insomnia, J. Clin. Psychiatry, 66(4), 469 (2005).
H.R. Khouzam, A review of trazodone use in psychiatric and medical conditions, Postgrad. Med., 129(1), 140-148 (2017).
B.A. Dijkstra, P.F. Krabbe, C.A. De Jong, C.P. van der Staak, Prediction of withdrawal symptoms during opioid detoxification, J. Opioid Manag., 4(5), 311-319 (2008).
R. Freynhagen, M. Backonja, S. Schug, Pregabalin for the treatment of drug and alcohol withdrawal symptoms: A comprehensive review, CNS Drugs, 30, 1191-1200 (2016).
R.S. Rosenson, S.K. Baker, T.A. Jacobson, S.L. Kopecky, B.A. Parker, An assessment by the Statin Muscle Safety Task Force, J. Clin. Lipidol., 8(3 Suppl), S58-71 (2014).
P. Haastrup, M.S. Paulsen, L.M. Begtrup, J.M. Hansen, D.E. Jarbøl, Strategies for discontinuation of proton pump inhibitors: A systematic review, Farm. Pract., 31(6), 625-630 (2014).
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
License
Copyright (c) 2020 Revista Colombiana de Ciencias Químico-Farmacéuticas
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Department of Pharmacy of the Faculty of Sciences of the National University of Colombia authorizes the photocopy of articles and texts for academic or internal purposes of the institutions, citing the source. The ideas issued by the authors are the express responsibility of these and it does not necessarily reflect the views of this journal.
The entire contents of this journal, except when is identified, are subject to a Creative Commons Attribution License 4.0 adopted by Colombia. Consult the regulation: http://co.creativecommons.org/?page_id=13